A Phase Ib Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged Disease or NUP98 Alterations

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT05886049

Study #:
STUDY00161561

Start Date:
Jun 06, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05886049

View Complete Trial Details & Eligibility at ClinicalTrials.gov